The A to I Editing Landscape in Melanoma and Its Relation to Clinical Outcome

Overview

Journal RNA Biol

Specialty Molecular Biology

Date 2022 Aug 22

PMID 35993275

Authors

Austeja Amweg

Marina Tusup

Phil Cheng

Ernesto Picardi

Reinhard Dummer

Mitchell P Levesque

Lars E French

Emmanuella Guenova

Severin Lauchli

Thomas Kundig

Mark Mellett

Steve Pascolo

Affiliations

Soon will be listed here.

Abstract

RNA editing refers to non-transient RNA modifications that occur after transcription and prior to translation by the ribosomes. RNA editing is more widespread in cancer cells than in non-transformed cells and is associated with tumorigenesis of various cancer tissues. However, RNA editing can also generate neo-antigens that expose tumour cells to host immunosurveillance. Global RNA editing in melanoma and its relevance to clinical outcome currently remain poorly characterized. The present study compared RNA editing as well as gene expression in tumour cell lines from melanoma patients of short or long metastasis-free survival, patients relapsing or not after immuno- and targeted therapy and tumours harbouring or mutations. Overall, our results showed that gene expression can be a marker of resistance to BRAF and MEK inhibition and gives some insights of candidate genes as potential biomarkers. In addition, this study revealed an increase in Adenosine-to-Inosine editing in Alu regions and in non-repetitive regions, including the hyperediting of the and genes in relapsed tumour samples during targeted therapy and of the gene in NRAS mutated melanoma cells. Therefore, RNA editing could be a promising tool for identifying predictive markers, tumour neoantigens and targetable pathways that could help in preventing relapses during immuno- or targeted therapies.

Citing Articles

Advances in A-to-I RNA editing in cancer.

Zhang Y, Li L, Mendoza J, Wang D, Yan Q, Shi L Mol Cancer. 2024; 23(1):280.

PMID: 39731127 PMC: 11673720. DOI: 10.1186/s12943-024-02194-6.

The diverse landscape of RNA modifications in cancer development and progression.

Kim H, Eun J, Jang S, Kim J, Jeong J Genes Genomics. 2024; 47(2):135-155.

PMID: 39643826 DOI: 10.1007/s13258-024-01601-y.

RNA editing enzymes: structure, biological functions and applications.

Zhang D, Zhu L, Gao Y, Wang Y, Li P Cell Biosci. 2024; 14(1):34.

PMID: 38493171 PMC: 10944622. DOI: 10.1186/s13578-024-01216-6.

The role of ADAR1 through and beyond its editing activity in cancer.

Jiao Y, Xu Y, Liu C, Miao R, Liu C, Wang Y Cell Commun Signal. 2024; 22(1):42.

PMID: 38233935 PMC: 10795376. DOI: 10.1186/s12964-023-01465-x.

Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response.

Perez-Banos A, Gleisner M, Flores I, Pereda C, Navarrete M, Araya J Br J Cancer. 2023; 129(4):572-585.

PMID: 37355722 PMC: 10421921. DOI: 10.1038/s41416-023-02327-6.

References

Gide T, Wilmott J, Scolyer R, Long G . Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Clin Cancer Res. 2017; 24(6):1260-1270. DOI: 10.1158/1078-0432.CCR-17-2267. View

Lezcano C, Shoushtari A, Ariyan C, Hollmann T, Busam K . Primary and Metastatic Melanoma With NTRK Fusions. Am J Surg Pathol. 2018; 42(8):1052-1058. PMC: 6041134. DOI: 10.1097/PAS.0000000000001070. View

Suliman B, Xu D, Williams B . The promyelocytic leukemia zinc finger protein: two decades of molecular oncology. Front Oncol. 2012; 2:74. PMC: 3398472. DOI: 10.3389/fonc.2012.00074. View

Blanc V, Davidson N . C-to-U RNA editing: mechanisms leading to genetic diversity. J Biol Chem. 2002; 278(3):1395-8. DOI: 10.1074/jbc.R200024200. View

Qian J, Chen Q, Yao D, Yang L, Yang J, Wen X . MOK overexpression is associated with promoter hypomethylation in patients with acute myeloid leukemia. Int J Clin Exp Pathol. 2015; 8(1):127-36. PMC: 4348826. View

Sun J, Carr M, Khushalani N . Principles of Targeted Therapy for Melanoma. Surg Clin North Am. 2019; 100(1):175-188. DOI: 10.1016/j.suc.2019.09.013. View

Vanneman M, Dranoff G . Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012; 12(4):237-51. PMC: 3967236. DOI: 10.1038/nrc3237. View

Yeh I, Botton T, Talevich E, Shain A, Sparatta A, De la Fouchardiere A . Activating MET kinase rearrangements in melanoma and Spitz tumours. Nat Commun. 2015; 6:7174. PMC: 4446791. DOI: 10.1038/ncomms8174. View

Futreal P, Coin L, Marshall M, Down T, Hubbard T, Wooster R . A census of human cancer genes. Nat Rev Cancer. 2004; 4(3):177-83. PMC: 2665285. DOI: 10.1038/nrc1299. View

10.

Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I . Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014; 5:3116. PMC: 4084638. DOI: 10.1038/ncomms4116. View

11.

Dannenmann S, Hermanns T, Bransi A, Matter C, von Boehmer L, Stevanovic S . Spontaneous peripheral T-cell responses toward the tumor-associated antigen cyclin D1 in patients with clear cell renal cell carcinoma. Cancer Immunol Res. 2014; 1(5):288-95. DOI: 10.1158/2326-6066.CIR-13-0113. View

12.

Barak M, Levanon E, Eisenberg E, Paz N, Rechavi G, Church G . Evidence for large diversity in the human transcriptome created by Alu RNA editing. Nucleic Acids Res. 2009; 37(20):6905-15. PMC: 2777429. DOI: 10.1093/nar/gkp729. View

13.

Melcher T, Maas S, Herb A, Sprengel R, Seeburg P, Higuchi M . A mammalian RNA editing enzyme. Nature. 1996; 379(6564):460-4. DOI: 10.1038/379460a0. View

14.

Arozarena I, Wellbrock C . Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer. 2019; 19(7):377-391. DOI: 10.1038/s41568-019-0154-4. View

15.

Hartner J, Schmittwolf C, Kispert A, Muller A, Higuchi M, Seeburg P . Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J Biol Chem. 2003; 279(6):4894-902. DOI: 10.1074/jbc.M311347200. View

16.

Chan T, Qamra A, Tan K, Guo J, Yang H, Qi L . ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer. Gastroenterology. 2016; 151(4):637-650.e10. PMC: 8286172. DOI: 10.1053/j.gastro.2016.06.043. View

17.

Purcell D, Chauhan S, Jimenez-Stinson D, Elliott K, Tsewang T, Lee Y . Novel CARM1-Interacting Protein, DZIP3, Is a Transcriptional Coactivator of Estrogen Receptor-α. Mol Endocrinol. 2015; 29(12):1708-19. PMC: 4664229. DOI: 10.1210/me.2015-1083. View

18.

Wahlstedt H, Daniel C, Enstero M, Ohman M . Large-scale mRNA sequencing determines global regulation of RNA editing during brain development. Genome Res. 2009; 19(6):978-86. PMC: 2694479. DOI: 10.1101/gr.089409.108. View

19.

Zhang M, Fritsche J, Roszik J, Williams L, Peng X, Chiu Y . RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nat Commun. 2018; 9(1):3919. PMC: 6156571. DOI: 10.1038/s41467-018-06405-9. View

20.

Litchfield K, Reading J, Puttick C, Thakkar K, Abbosh C, Bentham R . Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021; 184(3):596-614.e14. PMC: 7933824. DOI: 10.1016/j.cell.2021.01.002. View